Tislelizumab Combined With Lenvatinib and GEMOX Versus Tislelizumab Combined With GEMOX in Conversion Therapy of ICC and GBC.

Clinical trial NCT05620498 · UNKNOWN

Trial details

NCT number: NCT05620498
Sponsor: Tianjin Medical University Cancer Institute and Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

Start date: 2022-09-08
Primary completion: 2023-06-30
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.